Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 297, Issue 4, 2009, Pages

  Kemp, William ^a,b   Kompa, Andrew ^a   Phrommintikul, Arintaya ^a   Herath, Chandana ^c   Zhiyuan, Jia ^c   Angus, Peter ^c   McLean, Catriona ^b   Roberts, Stuart ^b   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cirrhosis; Liver disease; Portal hypertension

Indexed keywords

CYTOKINE; HYDROXYPROLINE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UROTENSIN II; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; UROTENSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEMODYNAMIC PARAMETERS; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; MORPHOMETRICS; NONHUMAN; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; GENETICS; INFUSION PUMP; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PORTAL VEIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TOXICITY; UPREGULATION; VASCULARIZATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYPROLINE; HYPERTENSION, PORTAL; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, SUBCUTANEOUS; LIVER; LIVER CIRRHOSIS; MALE; PORTAL PRESSURE; PORTAL SYSTEM; PROTO-ONCOGENE PROTEINS C-SIS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; UROTENSINS;

EID: 70349747023     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00127.2009     Document Type: Article

References (36)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286, 1999. (Pubitemid 129515542)
2. Asbert M, Gines A, Gines P, Jimenez W, Claria J, Salo J, Arroyo V, Rivera F, Rodes J. Circulating levels of endothelin in cirrhosis. Gastroenterology 104: 1485-1491, 1993.
3. Bergman I, Loxley R. New spectrophotometric method for the determination of proline in tissue hydrolyzates. Anal Chem 42: 702-706, 1970.
4. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130: 1865-1870, 2000.
5. Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27: 2919-2926, 2006. (Pubitemid 44584417)
6. Chatterjee S, Vrolix G, Depoortere I, Peeters T, Van Marck E. The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis. BMC Infect Dis 5: 45, 2005. (Pubitemid 41363781)
7. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95: 15803-15808, 1998. (Pubitemid 29018781)
8. Dai HY, Kang WQ, Wang X, Yu XJ, Li ZH, Tang MX, Xu DL, Li CW, Zhang Y, Ge ZM. The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept 140: 88-93, 2007. (Pubitemid 46316790)
9. Douglas SA, Dhanak D, Johns DG. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25: 76-85, 2004. (Pubitemid 38183393)
10. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131: 1262-1274, 2000.
11. Gardiner SM, March JE, Kemp PA, Bennett T. Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br J Pharmacol 143: 422-430, 2004. (Pubitemid 39424831)
12. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132: 1625-1629, 2001. (Pubitemid 32397953)
13. Gardiner SM, March JE, Kemp PA, Maguire JJ, Kuc RE, Davenport AP, Bennett T. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br J Pharmacol 147: 612-621, 2006.
14. Gerbes AL, Moller S, Gulberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 21: 735-739, 1995.
15. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37: 767-772, 2002. (Pubitemid 35404215)
16. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370: 238-250, 2004. (Pubitemid 40063823)
17. Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, Roberts S. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 27: 1232-1239, 2007. (Pubitemid 47543152)
18. Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 25: 1783-1788, 2004. (Pubitemid 39346221)
19. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266: 174-178, 1999. (Pubitemid 30028787)
20. Moller S, Emmeluth C, Henriksen JH. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol 19: 285-290, 1993. (Pubitemid 23363037)
21. Moller S, Gulberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 23: 135-144, 1995. (Pubitemid 27366208)
22. Moller S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 56: 481-490, 1996.
23. Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D, Lee SS. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 37: 393-400, 2003. (Pubitemid 36152539)
24. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckles SP, Civelli O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1: 383-385, 1999. (Pubitemid 129493582)
25. Russell FD, Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res 63: 673-681, 2004. (Pubitemid 39078681)
26. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132: 5-9, 2001. (Pubitemid 32128427)
27. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88: 1102-1104, 2001. (Pubitemid 34132508)
28. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44: 1679-1689, 2004. (Pubitemid 39369804)
29. Shi L, Ding W, Li D, Wang Z, Jiang H, Zhang J, Tang C. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188: 260-264, 2006. (Pubitemid 44313921)
30. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, MacLean MR. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280: H925-H928, 2001. (Pubitemid 32466939)
31. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N, Probsting AS, Clemens C, Lammert F, Sauerbruch T, Heller J. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47: 1264-1276, 2008. (Pubitemid 351547913)
32. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246-253, 2003. (Pubitemid 36993236)
33. Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 29: 375-387, 2006. (Pubitemid 44102804)
34. Watanabe T, Suguro T, Kanome T, Sakamoto Y, Kodate S, Hagiwara T, Hongo S, Hirano T, Adachi M, Miyazaki A. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46: 738-744, 2005. (Pubitemid 43186747)
35. Zhang YG, Li YG, Liu BG, Wei RH, Wang DM, Tan XR, Bu DF, Pang YZ, Tang CS. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin 28: 36-43, 2007. (Pubitemid 46046624)
36. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, Sauerbruch T, Heller J. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 55: 1296-1305, 2006. (Pubitemid 44277362)